Efficacy of dasatinib against ponatinib-resistant chronic myeloid leukemia cells

Leuk Lymphoma. 2020 Jan;61(1):237-239. doi: 10.1080/10428194.2019.1660971. Epub 2019 Sep 10.

Authors

Seiichi Okabe¹, Yuko Tanaka¹, Mitsuru Moriyama¹, Akihiko Gotoh¹

Affiliation

¹ Department of Hematology, Tokyo Medical University, Tokyo, Japan.

PMID: 31502898
DOI: 10.1080/10428194.2019.1660971

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents* / pharmacology
Antineoplastic Agents* / therapeutic use
Dasatinib / pharmacology
Dasatinib / therapeutic use
Humans
Imidazoles / pharmacology
Imidazoles / therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / genetics
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use
Pyridazines* / pharmacology
Pyridazines* / therapeutic use

Substances

Antineoplastic Agents
Imidazoles
Protein Kinase Inhibitors
Pyridazines
ponatinib
Dasatinib